A red and green candlestick chart shows a downward trend, indicating a stock market decline.

Iridex (NASDAQ: IRIX) Shares Fall 26.96% After Hours: What Investors Should Know

Iridex Corporation (NASDAQ:IRIX) shares fell 26.96% to $0.51 in after-hours trading on Tuesday, following the company’s third-quarter results and a reduction in its full-year 2026 revenue guidance.

Based in San Jose, California, Iridex develops and manufactures laser-based medical systems, delivery devices and accessories used to treat glaucoma and retinal diseases.

Iridex Reports Third-Quarter Results

Iridex reported third-quarter revenue of $10.16 million, down 19% year over year from $12.48 million and approximately 19.7% below the analyst estimate of $12.64 million.

Retina product revenue declined to $5.1 million from $6.7 million in the prior-year quarter, while revenue from the Cyclo G6 product family fell to $3.2 million from $3.5 million.

Gross margin improved to 42.4% from 32.1% a year earlier. Excluding a one-time inventory write-off recorded in the prior-year period, the company said its comparable gross margin improved by 370 basis points to 38.7%.

The company reported a GAAP net loss of $1.4 million, or $0.08 per share, compared with a loss of $1.6 million, or $0.09 per share, a year earlier. Adjusted EBITDA loss widened to $0.6 million from $0.1 million.

Company Cuts 2026 Revenue Guidance

Iridex lowered its full-year 2026 revenue forecast to between $46 million and $48 million, from its previous range of $51 million to $53 million. The guidance excludes revenue from the Middle East.

CEO Patrick Mercer attributed the revenue shortfall to weaker-than-expected demand in Europe and Asia, distributor inventory reductions and regulatory challenges.

The company is also reviewing its product lines and shifting resources toward more profitable opportunities. Mercer said Iridex expects to enter 2027 with better margins, a lower cost base and a business model more focused on cash flow generation.

Trading Metrics, Technical Analysis

Iridex has a market capitalization of approximately $12.25 million.

Over the past year, Iridex shares have fallen 24.77%.

The stock has traded between a 52-week high of $1.65 and a low of $0.61.

Benzinga’s Edge Stock Rankings show a negative price trend across short-, medium- and long-term time frames.

Price Action: IRIX closed regular trading up 1.72% at $0.70 on Tuesday.

Photo: Sandinashr / Shutterstock

Market News and Data brought to you by Benzinga APIs
Share this article